IRIS
FRANCHINA, Tindara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.788
NA - Nord America 5.206
AS - Asia 2.549
SA - Sud America 837
Continente sconosciuto - Info sul continente non disponibili 203
AF - Africa 80
OC - Oceania 4
Totale 14.667
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.079
RU - Federazione Russa 2.950
SG - Singapore 1.038
CN - Cina 729
BR - Brasile 709
SE - Svezia 606
IE - Irlanda 586
IT - Italia 354
PL - Polonia 302
FR - Francia 295
HK - Hong Kong 276
DE - Germania 179
VN - Vietnam 145
UA - Ucraina 121
GB - Regno Unito 115
FI - Finlandia 102
IN - India 85
CA - Canada 53
BD - Bangladesh 50
AT - Austria 46
AR - Argentina 42
MX - Messico 34
BE - Belgio 33
ID - Indonesia 30
IQ - Iraq 28
ZA - Sudafrica 28
UZ - Uzbekistan 24
EC - Ecuador 23
TR - Turchia 22
CO - Colombia 19
NL - Olanda 19
JP - Giappone 16
PH - Filippine 15
VE - Venezuela 15
ES - Italia 14
PK - Pakistan 14
JM - Giamaica 13
NP - Nepal 12
CZ - Repubblica Ceca 11
MA - Marocco 11
CL - Cile 9
AL - Albania 8
CR - Costa Rica 8
EE - Estonia 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
LT - Lituania 7
TN - Tunisia 7
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
EU - Europa 6
KE - Kenya 6
PY - Paraguay 6
BO - Bolivia 5
JO - Giordania 5
MY - Malesia 5
UY - Uruguay 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LK - Sri Lanka 4
PA - Panama 4
RO - Romania 4
CH - Svizzera 3
GT - Guatemala 3
HR - Croazia 3
IR - Iran 3
PE - Perù 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
GA - Gabon 2
GE - Georgia 2
HN - Honduras 2
IL - Israele 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
ET - Etiopia 1
Totale 14.458
Salva come PNG Salva come JPEG
Città #
Moscow 840
Ashburn 719
Dublin 583
Singapore 546
Chandler 489
Dallas 423
Nyköping 294
Warsaw 291
Hong Kong 276
Jacksonville 246
Beijing 243
San Jose 233
New York 150
Council Bluffs 144
The Dalles 137
Messina 127
Los Angeles 123
Ann Arbor 97
Princeton 94
Dearborn 93
Lauterbourg 83
Medford 82
Cambridge 74
Des Moines 72
São Paulo 56
Buffalo 47
Ho Chi Minh City 45
Munich 44
Boardman 41
Santa Clara 40
Vienna 39
Tianjin 37
Woodbridge 36
Brussels 33
Frankfurt am Main 28
Pune 28
Orem 26
Atlanta 25
Dong Ket 24
San Mateo 23
Wilmington 23
Jinan 22
Chicago 21
Hanoi 21
Shenyang 21
Tashkent 21
Redondo Beach 20
Montreal 19
Belo Horizonte 18
Brooklyn 18
Guangzhou 18
Jakarta 18
London 18
San Francisco 18
Turku 18
Chennai 17
Lancaster 17
Phoenix 17
Stockholm 17
Johannesburg 16
Nanjing 16
Rio de Janeiro 16
Helsinki 15
Brasília 14
Fort Washington 14
Grammichele 14
Houston 14
Shanghai 14
Tokyo 14
Amsterdam 12
Boston 12
Curitiba 12
Denver 12
Hebei 12
Rome 12
Manchester 11
Mexico City 11
Quito 11
Toronto 11
Campinas 10
Milan 10
Nuremberg 10
Porto Alegre 10
Taizhou 10
Mumbai 9
Paternò 9
Seattle 9
Shenzhen 9
Zhengzhou 9
Baghdad 8
Caracas 8
Columbus 8
Duque de Caxias 8
Düsseldorf 8
Hangzhou 8
Leawood 8
Miami 8
Da Nang 7
Dhaka 7
Goiânia 7
Totale 7.836
Salva come PNG Salva come JPEG
Nome #
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 394
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System 256
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 246
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 239
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 233
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 221
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 218
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 212
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 207
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 202
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 198
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 198
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 192
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 188
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 186
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 182
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 178
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 177
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 176
Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days) 176
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 174
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 174
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 173
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 173
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 168
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database 167
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 166
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 165
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 165
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 164
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 164
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 163
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 160
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 158
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 157
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 156
Challenges and promises of physical exercise in advances lung cancer patients 154
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 151
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 151
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 151
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 149
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 148
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 148
Embolia polmonare 147
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 147
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 144
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. 143
Impact of single-nucleotide polymorphisms in genes coding for folate pathway enzymes on efficacy/toxicity of gemcitabine and pemetrexed based therapy in advanced non small cell lung cancer (NSCLC): new prospectives for old markers. 142
Emerging targeted therapies for castration-resistant prostate cancer 141
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 140
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 138
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 137
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 134
NSCLC and HER2: between lights and shadows 134
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 134
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 133
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 128
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 128
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 127
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 126
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 125
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 123
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 122
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 122
Molecular and clinical analysis of predictive biomarkers to anti-EGFR inhibitors in metastatic colorectal cancer (mCRC): Interaction among early tumor shrinkage, skin toxicities, and RAS status. 121
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 120
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 117
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 114
Neoplasie della testa collo nell’ anziano 111
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 109
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 109
Rare histotypes of epithelial biliary tract tumors: A literature review 108
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 107
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 106
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 105
Turbe della nutrizione: anoressia e cachessia. 104
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 101
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 100
Listening understanding and acting (lung): Focus on communicational issue in thoracic oncology 100
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 98
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 97
Neoplasie della Testa e del Collo nell'anziano 94
POLIMORPHISM OF METHYLENE-TETRAHYDROFOLATE REDUCTASE AND RISK OF LUNG AND COLON-RECTAL CANCER: A CASE CONTROL STUDY 93
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 92
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 92
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 88
“Lunga stazionarietà di malattia e clinical benefit con erlotinib in un paziente anziano, forte fumatore, affetto da carcinoma squamoso del polmone”. 88
Invecchiamento e cancro. 85
Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice 84
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. 84
Use of nivolumab in elderly patients with advanced Non-Squamous NSCLC: results from the Italian Expanded Access Program (EAP) 84
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings 81
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 78
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database 77
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 76
FGFR a promising druggable target in cancer: Molecular biology and new drugs 76
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 76
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 73
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System 72
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review 70
Totale 14.183
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.188
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.188
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022662 0 71 23 19 28 7 29 27 5 163 90 200
2022/20231.841 128 179 74 157 136 184 49 129 724 9 49 23
2023/2024495 25 80 32 29 23 175 60 4 2 21 8 36
2024/20252.055 34 22 34 112 104 82 57 451 473 156 192 338
2025/20266.718 332 378 474 431 551 1.403 862 914 824 293 110 146
2026/2027828 184 644 0 0 0 0 0 0 0 0 0 0
Totale 14.667